Literature DB >> 6969724

Mutual pro-drugs of beta-lactam antibiotics and beta-lactamase inhibitors.

B Baltzer, E Binderup, W von Daehne, W O Godtfredsen, K Hansen, B Nielsen, H Sørensen, S Vangedal.   

Abstract

The principle of combining a beta-lactam antibiotic with a beta-lactamase inhibitor in a single molecule functioning as pro-drug for the two active components is illustrated by the linked esters 3 and 4 in which ampicillin and mecillinam, respectively, are combined with the beta-lactamase inhibitor penicillanic acid sulfone. It is shown that in man these esters are excellently absorbed from the gastro-intestinal tract and after absorption hydrolyzed with simultaneous liberation of the active components. As a result high blood and tissue levels of antibiotic and beta-lactamase inhibitor in a balanced ratio are attained. The advantages of "mutual pro-drugs" over simple combinations are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6969724     DOI: 10.7164/antibiotics.33.1183

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

2.  Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 3.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

Review 4.  Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

Authors:  R Sutherland
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

Review 5.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

6.  Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.

Authors:  Sandeep Rana; Smit Kour; Yogesh A Sonawane; Caroline M Robb; Jacob I Contreras; Smitha Kizhake; Muhammad Zahid; Adam R Karpf; Amarnath Natarajan
Journal:  Chem Biol Drug Des       Date:  2020-04-22       Impact factor: 2.817

7.  The molecular basis for the mode of action of Beta-lactam antibiotics and mechanisms of resistance.

Authors:  B W Bycroft; R E Shute
Journal:  Pharm Res       Date:  1985-01       Impact factor: 4.200

Review 8.  Disulfide based prodrugs for cancer therapy.

Authors:  Qiang Wang; Jiankun Guan; Jiangling Wan; Zifu Li
Journal:  RSC Adv       Date:  2020-06-25       Impact factor: 4.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.